AbCellera Announces Collaboration with Moderna to Discover Therapeutic Antibodies for mRNA Medicines

Partnership combines AbCellera’s AI-powered antibody discovery platform with Moderna’s mRNA technology platform to accelerate the development of mRNA-encoded antibody therapeutics across multiple indications

VANCOUVER, Canada I September 15, 2021 I AbCellera (Nasdaq: ABCL) announced today that it entered into a multi-year, multi-target research collaboration and license agreement with Moderna to leverage AbCellera’s AI-powered technology to search and analyze natural immune responses to identify therapeutic antibodies against up to six targets selected by Moderna.

“Over the past year, Moderna has demonstrated the speed and impact of its mRNA vaccine technology in helping to protect people around the world,” said Carl Hansen, Ph.D., CEO and President of AbCellera. “We are excited to work alongside their team to advance RNA-encoded antibodies as a new frontier in genetic medicines.”

Under the terms of the agreement, Moderna will have the rights to develop and commercialize antibodies resulting from the collaboration. AbCellera will receive research payments and is eligible to receive from Moderna downstream clinical and commercial milestone payments and royalties on net sales of products.

About AbCellera Biologics Inc.

AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more information, please visit www.abcellera.com.

SOURCE: AbCellera Biologics

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top